14-day Premium Trial Subscription Try For FreeTry Free

Stocks To Watch: 0% To The Rescue?

12:49pm, Saturday, 14'th Mar 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
Homology Medicines (NASDAQ:FIXX)‘s stock had its “buy” rating reiterated by investment analysts at Chardan Capital in a research report issued on Friday, TipRanks reports. They currently have a
Homology Medicines (NASDAQ:FIXX)‘s stock had its “buy” rating reiterated by HC Wainwright in a report released on Friday, TipRanks reports. They currently have a $36.00 price target on the stock
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Collegium Pharmaceutical (COLL) and Homology Medicines
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Collegium Pharmaceutical
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aerie Pharma (AERI) and Homology Medicines (FIXX) with
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aerie Pharma ( AERI – Research Report ) and Homology Medicines ( FIXX – Research Report ) with bull
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Homology Medicines (FIXX) and X4 Pharmaceuticals (XFOR)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Homology Medicines
Homology Medicines (FIXX) delivered earnings and revenue surprises of 23.61% and 40.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Homology Medicines (FIXX) delivered earnings and revenue surprises of 23.61% and 40.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Homology Medicines Inc:

Homology Medicines: 4Q Earnings Snapshot

08:43pm, Thursday, 12'th Mar 2020
BEDFORD, Mass. (AP) _ Homology Medicines Inc. (FIXX) on Thursday reported a loss of $24.2 million in its fourth quarter. The Bedford, Massachusetts-based company said it had a loss of 55 cents per sh
- Announced Encouraging Initial Clinical Data From the Phase 1/2 pheNIX PKU Gene Therapy Trial and Expects to Select Dose for Randomized, Concurrently Controlled Expansion.
- Announced Encouraging Initial Clinical Data From the Phase 1/2 pheNIX PKU Gene Therapy Trial and Expects to Select Dose for Randomized, Concurrently...
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE